Skip to main content
SpringerLink
Log in

Neuroinflammation in Parkinson’s Disease Animal Models: A Cell Stress Response or a Step in Neurodegeneration?

  • Chapter
  • First Online:
Book cover Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 22))

Abstract

The motor symptoms of Parkinson’s disease are due to the progressive degeneration of dopaminergic neurons in the substantia nigra. Multiple neuroinflammatory processes are exacerbated in Parkinson’s disease, including glial-mediated reactions, increased expression of proinflammatory substances, and lymphocytic infiltration, particularly in the substantia nigra. Neuroinflammation is also implicated in the neurodegeneration and consequent behavioral symptoms of many Parkinson’s disease animal models, although it is not clear whether these features emulate pathogenic steps in the genuine disorder or if some inflammatory features provide protective stress responses. Here, we compare and summarize findings on neuroinflammatory responses and effects on behavior in a wide range of toxin-based, inflammatory and genetic Parkinson’s disease animal models.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abeliovich A, Schmitz Y, Fariñas I et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239–252

    CAS  PubMed  Google Scholar 

  • Akiyama H, McGeer PL (1989) Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 489(2):247–253

    CAS  PubMed  Google Scholar 

  • Alberio T, Lopiano L and Fasano M (2012) Cellular models to investigate biochemical pathways in Parkinson’s disease. FEBS J279. doi:10.1111/j.1742-4658.2012.08516.x

    Google Scholar 

  • Ambrosi G, Armentero MT, Levandis G et al (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson’s disease. Brain Res Bull 82(1–2):29–38

    CAS  PubMed  Google Scholar 

  • Armentero MT, Levandis G, Nappi G et al (2006) Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund’s adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson’s disease. Neurobiol Dis 24(3):492–505

    CAS  PubMed  Google Scholar 

  • Baldereschi M, Inzitari M, Vanni P et al (2008) Pesticide exposure might be a strong risk factor for Parkinson’s disease. Ann Neurol 63(1):128

    PubMed  Google Scholar 

  • Barcia C, Ros CM, Annese V et al (2011) IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. Cell Death Dis 2:e142

    PubMed Central  CAS  PubMed  Google Scholar 

  • Barkholt P, Sanchez-Guajardo V, Kirik D et al (2012) Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience 208:85–96

    CAS  PubMed  Google Scholar 

  • Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson’s disease. Prog Brain Res 184:113–132

    CAS  PubMed  Google Scholar 

  • Betarbet R, Sherer TB, MacKenzie G et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3(12):1301–1306

    CAS  PubMed  Google Scholar 

  • Bichler Z, Lim HC, Zeng L, Tan EK (2013) Non-motor and motor features in LRRK2 transgenic mice. PLoS One 8(7):e70249

    PubMed Central  CAS  PubMed  Google Scholar 

  • Biskup S, Moore DJ, Celsi F et al (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60(5):557–569

    CAS  PubMed  Google Scholar 

  • Blandini F (2013) Neural and immune mechanisms in the pathogenesis of Parkinson’s disease. Funct Neurol 28(1):5

    PubMed Central  PubMed  Google Scholar 

  • Bobyn J, Mangano EN, Gandhi A et al (2012) Viral-toxin interactions and Parkinson’s disease: poly I: C priming enhanced the neurodegenerative effects of paraquat. J Neuroinflammation 9:86

    PubMed Central  CAS  PubMed  Google Scholar 

  • Bové J, Perier C (2012) Neurotoxin-based models of Parkinson’s disease. Neuroscience 211:51–76

    PubMed  Google Scholar 

  • Braak H, Del Tredici K (2010) Pathophysiology of sporadic Parkinson’s disease. Fortschr Neurol Psychiatr 78(Suppl 1):2–4

    Google Scholar 

  • Brochard V, Combadière B, Prigent A et al (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119(1):182–192

    PubMed Central  CAS  PubMed  Google Scholar 

  • Bronstein DM, Perez-Otano I, Sun V et al (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 704(1):112–116

    CAS  PubMed  Google Scholar 

  • Bungeroth M, Appenzeller S, Regulin A, Völker W et al (2014) Differential aggregation properties of alpha-synuclein isoforms. Neurobiol Aging S0197–4580(14):00201–00202

    Google Scholar 

  • Carvey PM, Chang Q, Lipton JW et al (2003) Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson’s disease. Front Biosci 8:826–837

    Google Scholar 

  • Casarejos MJ, Menéndez J, Solano RM et al (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97(4):934–946

    CAS  PubMed  Google Scholar 

  • Castaño A, Herrera AJ, Cano J et al (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70(4):1584–1592

    PubMed  Google Scholar 

  • Castaño A, Herrera AJ, Cano J et al (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 81(1):150–157

    PubMed  Google Scholar 

  • Cebrián C, Zucca FA, Mauri P et al (2014) MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun 16(5):3633

    Google Scholar 

  • Chesselet MF (2008) In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson’s disease? Exp Neurol 209(1):22–27

    PubMed Central  CAS  PubMed  Google Scholar 

  • Choi DY, Liu M, Hunter RL et al (2009) Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4(5):e5482

    PubMed Central  PubMed  Google Scholar 

  • Chung YC, Kim SR, Jin BK (2010) Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson’s disease. J Immunol 185(2):1230–1237

    CAS  PubMed  Google Scholar 

  • Cicchetti F, Brownell AL, Williams K et al (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15(6):991–998

    CAS  PubMed  Google Scholar 

  • Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30(9):475–483

    CAS  PubMed  Google Scholar 

  • Cicchetti F, Lapointe N, Roberge-Tremblay A et al (2005) Systemic exposure to paraquat and maneb models early Parkinson’s disease in young adult rats. Neurobiol Dis 20(2):360–371

    CAS  PubMed  Google Scholar 

  • Clark IE, Dodson MW, Jiang C et al (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441:1162–1166

    CAS  PubMed  Google Scholar 

  • Collins LM, Toulouse A, Connor TJ et al (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 62(7):2154–2168

    CAS  PubMed  Google Scholar 

  • Conway KA, Harper JD, Lansbury PT Jr (2000a) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39(10):2552–2563

    CAS  PubMed  Google Scholar 

  • Conway KA, Lee SJ, Rochet JC et al (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571–576

    PubMed Central  CAS  PubMed  Google Scholar 

  • Correia Guedes L, Ferreira JJ, Rosa MM et al (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 16(4):237–242

    CAS  PubMed  Google Scholar 

  • Corti O, Brice A (2013) Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson’s disease. Curr Opin Neurobiol 23:100–108

    CAS  PubMed  Google Scholar 

  • Couch Y, Alvarez-Erviti L, Sibson NR et al (2011) The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation 8:166

    PubMed Central  CAS  PubMed  Google Scholar 

  • Cuervo AM, Stefanis L, Fredenburg R et al (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292–1295

    CAS  PubMed  Google Scholar 

  • Członkowska A, Kohutnicka M, Kurkowska-Jastrzebska I et al (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson’s disease mice model. Neurodegeneration 5(2):137–143

    PubMed  Google Scholar 

  • Daher JP, Volpicelli-Daley LA1, Blackburn JP et al (2014) Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci USA (in press)

    Google Scholar 

  • Damier P, Hirsch EC, Zhang P et al (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52(1):1–6

    CAS  PubMed  Google Scholar 

  • Danoy P, Pryce K, Hadler J et al (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet 6(12):e1001195

    PubMed Central  PubMed  Google Scholar 

  • Dauer W, Kholodilov N, Vila M et al (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99(22):14524–14529

    PubMed Central  CAS  PubMed  Google Scholar 

  • Davis GC, Williams AC, Markey SP et al (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1(3):249–254

    CAS  PubMed  Google Scholar 

  • Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 66(5):646–661

    PubMed Central  CAS  PubMed  Google Scholar 

  • de Meira Santos Lima M, Braga Reksidler A, Marques Zanata S et al (2006) Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101(1):117–125

    PubMed  Google Scholar 

  • De Pablos RM, Herrera AJ, Villarán RF et al (2005) Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J 19(3):407–409

    PubMed  Google Scholar 

  • Del Tredici K, Braak H (2012) Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord 27(5):597–607

    PubMed  Google Scholar 

  • Deleidi M, Hallett PJ, Koprich JB et al (2010) The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 30(48):16091–16101

    PubMed Central  CAS  PubMed  Google Scholar 

  • Deng H, Yuan L (2014) Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev. 2014 Apr 21. pii: S1568–1637(14):00048–8

    Google Scholar 

  • Desai VG, Feuers RJ, Hart RW et al (1996) MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res 715(1–2):1–8

    CAS  PubMed  Google Scholar 

  • Drolet RE, Sanders JM, Kern JT (2011) Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions. J Neurogenet 25(4):140–151

    CAS  PubMed  Google Scholar 

  • Dusonchet J, Kochubey O, Stafa K et al (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2. J Neurosci 31(3):907–912

    CAS  PubMed  Google Scholar 

  • Dutta G, Zhang P, Liu B (2008) The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22(5):453–464

    PubMed Central  CAS  PubMed  Google Scholar 

  • Dzamko N, Inesta-Vaquera F, Zhang J et al (2012) The IkappaB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7(6):e39132

    PubMed Central  CAS  PubMed  Google Scholar 

  • Emmer KL, Waxman EA, Covy JP et al (2011) E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem 286(40):35104–35118

    PubMed Central  CAS  PubMed  Google Scholar 

  • Engelhardt B, Coisne C (2011) Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8(1):4

    PubMed Central  PubMed  Google Scholar 

  • Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T et al (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130(Pt 3):799–815

    PubMed  Google Scholar 

  • Esposito E, Impellizzeri D, Mazzon E et al (2012) Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson’s disease. PLoS One 7(8):e41880

    PubMed Central  CAS  PubMed  Google Scholar 

  • Fang F, Wirdefeldt K, Jacks A et al (2012) CNS infections, sepsis and risk of Parkinson’s disease. Int J Epidemiol 41(4):1042–1049

    PubMed Central  PubMed  Google Scholar 

  • Fleming SM, Salcedo J, Fernagut PO et al (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24(42):9434–9440

    CAS  PubMed  Google Scholar 

  • Foix C, Nicolesco J (1925) Anatomie cérébrale. Les noyaux gris centraux et la región Mésencéphalo-sous-optique., Suivi d’un apéndice sur l’anatomie pathologique de la maladie de Parkinson. Masson et Cie, eds (Paris), 508–538

    Google Scholar 

  • Fortin DL, Nemani VM, Voglmaier SM et al (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25(47):10913–10921

    CAS  PubMed  Google Scholar 

  • Franzén B, Duvefelt K, Jonsson C, Engelhardt B et al (2003) Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res 115(2):130–146

    PubMed  Google Scholar 

  • Frank-Cannon TC, Alto LT, McAlpine FE et al (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 16(4):47

    Google Scholar 

  • Frank-Cannon TC, Tran T, Ruhn KA et al (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 28(43):10825–10834

    PubMed Central  CAS  PubMed  Google Scholar 

  • Fulceri F, Biagioni F, Lenzi P et al (2006) Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures. Ann N Y Acad Sci 1074:344–348

    CAS  PubMed  Google Scholar 

  • Gao JJ, Diesl V, Wittmann T et al (2002a) Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol 72(6):1234–1245

    CAS  PubMed  Google Scholar 

  • Gao HM, Hong JS, Zhang W et al (2002b) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22(3):782–790

    CAS  PubMed  Google Scholar 

  • Gao HM, Kotzbauer PT, Uryu K et al (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28(30):7687–7698

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gao HM, Liu B, Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23(15):6181–6187

    CAS  PubMed  Google Scholar 

  • Gao HM, Zhang F, Zhou H et al (2011) Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 119(6):807–814

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gardet A, Benita Y, Li C et al (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185(9):5577–5585

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gayle DA, Ling Z, Tong C et al (2002) Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 133(1):27–35

    CAS  PubMed  Google Scholar 

  • Geng Y, Fang M, Wang J et al (2011) Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of NF-κB and MAP kinases in lipopolysaccharide-treated PC12 cells. Phytother Res 26(3):337–343

    PubMed  Google Scholar 

  • George S, van den Buuse M, San Mok S, Masters CL et al (2008) Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 210(2):788–792

    CAS  PubMed  Google Scholar 

  • Ghosh A, Kanthasamy A, Joseph J et al (2012) Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson’s disease. J Neuroinflammation 9:241

    PubMed Central  CAS  PubMed  Google Scholar 

  • Giasson BI, Duda JE, Quinn SM et al (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34(4):521–533

    CAS  PubMed  Google Scholar 

  • Gillardon F, Schmid R, Draheim H (2012) Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41–48

    CAS  PubMed  Google Scholar 

  • Gispert S, Ricciardi F, Kurz A et al (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PloS ONE 4:e5777

    PubMed Central  PubMed  Google Scholar 

  • Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55–66

    CAS  PubMed  Google Scholar 

  • Goes AT, Souza LC, Filho CB et al (2014) Neuroprotective effects of swimming training in a mouse model of Parkinson’s disease induced by 6-hydroxydopamine. Neuroscience 256C:61–71

    Google Scholar 

  • Goldberg MS, Fleming SM, Palacino JJ et al (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628–43635

    CAS  PubMed  Google Scholar 

  • Gombash SE, Manfredsson FP, Kemp CJ et al (2013) Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 8(11):e81426

    PubMed Central  PubMed  Google Scholar 

  • Gomez-Isla T, Irizarry MC, Mariash A, Cheung B et al (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 24(2):245–258

    CAS  PubMed  Google Scholar 

  • Gomide V, Bibancos T, Chadi G (2005) Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools. Int J Neurosci 115(4):557–582

    CAS  PubMed  Google Scholar 

  • González H, Contreras F, Prado C, Elgueta D et al (2013) Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson’s disease. J Immunol 190(10):5048–5056

    PubMed  Google Scholar 

  • Graham DR, Sidhu A (2010) Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res 88(8):1777–1783

    PubMed Central  CAS  PubMed  Google Scholar 

  • Greggio E, Jain S, Kingsbury A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23(2):329–341

    CAS  PubMed  Google Scholar 

  • Grünblatt E, Mandel S, Maor G et al (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson’s disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78(1):1–12

    PubMed  Google Scholar 

  • Guo JL, Covell DJ, Daniels JP et al (2013) Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154(1):103–117

    CAS  PubMed  Google Scholar 

  • Gupta A, Kumar A, Kulkarni SK (2011) Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Prog Neuropsychopharmacol Biol Psychiatry 35(4):974–981

    CAS  PubMed  Google Scholar 

  • Gupta SP, Patel S, Yadav S et al (2010) Involvement of nitric oxide in maneb- and paraquat-induced Parkinson’s disease phenotype in mouse: is there any link with lipid peroxidation? Neurochem Res 35(8):1206–1213

    CAS  PubMed  Google Scholar 

  • Hancock DB, Martin ER, Mayhew GM et al (2008) Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study. BMC Neurol 8:6. doi:10.1186/1471-2377-8-6

    PubMed Central  PubMed  Google Scholar 

  • Harkavyi A, Abuirmeileh A, Lever R et al (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation 5:19

    PubMed Central  PubMed  Google Scholar 

  • Harms AS, Barnum CJ, Ruhn KA et al (2011) Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson’s disease. Mol Ther 19(1):46–52

    PubMed Central  CAS  PubMed  Google Scholar 

  • Harms AS, Cao S, Rowse AL et al (2013) MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33(23):9592–9600

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hattori N, Kitada T, Matsumine H et al (1998) Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 44(6):935–941

    CAS  PubMed  Google Scholar 

  • He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909(1–2):187–193

    CAS  PubMed  Google Scholar 

  • Healy DG, Falchi M, O’Sullivan SS et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 7(7):583–590

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hennis MR, Marvin MA, Taylor CM, Goldberg MS (2014) Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson’s disease. Neurobiol Dis 62:113–123

    PubMed Central  CAS  PubMed  Google Scholar 

  • Henry J, Smeyne RJ, Jang H et al (2010) Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord 16(9):566–571

    PubMed  Google Scholar 

  • Hernández-Romero MC, Argüelles S, Villarán RF et al (2008) Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J Neurochem 105(2):445–459

    PubMed  Google Scholar 

  • Herva ME, Zibaee S, Fraser G, Barker RA et al (2014) Anti-amyloid compounds inhibit alpha-synuclein aggregation induced by Protein Misfolding Cyclic Amplification (PMCA). J Biol Chem (in press)

    Google Scholar 

  • Hinkle KM, Yue M, Behrouz B et al (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener 7:25

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8(4):382–397

    CAS  PubMed  Google Scholar 

  • Hoban DB, Connaughton E, Connaughton C et al (2013) Further characterisation of the LPS model of Parkinson’s disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav Immun 27(1):91–100

    CAS  PubMed  Google Scholar 

  • Hoepken HH, Gispert S, Morales B et al (2007) Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25:401–411

    CAS  PubMed  Google Scholar 

  • Hunter RL, Cheng B, Choi DY et al (2009) Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87(8):1913–1921

    PubMed Central  CAS  PubMed  Google Scholar 

  • Iravani MM, Leung CC, Sadeghian M et al (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22(2):317–330

    PubMed  Google Scholar 

  • Itier JM, Ibanez P, Mena MA et al (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277–2291

    CAS  PubMed  Google Scholar 

  • Izumi Y, Ezumi M, Takada-Takatori Y, Akaike A et al (2014) Endogenous dopamine is involved in the herbicide paraquat-induced dopaminergic cell death. Toxicol Sci (in press)

    Google Scholar 

  • Janezic S, Threlfell S, Dodson PD, Dowie MJ et al (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci USA 110(42):E4016–E4025

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376

    CAS  PubMed  Google Scholar 

  • Johnston LC, Su X, Maguire-Zeiss K et al (2008) Human interleukin-10 gene transfer is protective in a rat model of Parkinson’s disease. Mol Ther 16(8):1392–1399

    PubMed Central  CAS  PubMed  Google Scholar 

  • Jung BD, Shin EJ, Nguyen XK et al (2010) Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 56(2):229–244

    CAS  PubMed  Google Scholar 

  • Kahle PJ, Waak J, Gasser T (2009) DJ-1 and prevention of oxidative stress in Parkinson’s disease and other age-related disorders. Free Radic Biol Med 47(10):1354–1361

    CAS  PubMed  Google Scholar 

  • Kamel F, Tanner C, Umbach D et al (2007) Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol 165(4):364–374

    CAS  PubMed  Google Scholar 

  • Kasten M, Klein C (2013) The many faces of alpha-synuclein mutations. Mov Disord 28(6):697–701

    PubMed  Google Scholar 

  • Kim B, Yang MS, Choi D et al (2012) Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7(4):e34693

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kirik D, Annett LE, Burger C et al (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease. Proc Natl Acad Sci USA 100(5):2884–2889

    PubMed Central  CAS  PubMed  Google Scholar 

  • Kirik D, Rosenblad C, Burger C et al (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22(7):2780–2791

    CAS  PubMed  Google Scholar 

  • Kitada T, Asakawa S, Hattori N et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608

    CAS  PubMed  Google Scholar 

  • Kitada T, Pisani A, Porter DR et al (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci 104:11441–11446

    PubMed Central  CAS  PubMed  Google Scholar 

  • Klementiev B, Li S, Korshunova I et al (2014) Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. J Neuroinflammation 11:27

    PubMed Central  PubMed  Google Scholar 

  • Klintworth H, Garden G, Xia Z (2009) Rotenone and paraquat do not directly activate microglia or induce inflammatory cytokine release. Neurosci Lett 462(1):1–5

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ko HS, von Coelln R, Sriram SR et al (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, pp38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25:7968–7978

    CAS  PubMed  Google Scholar 

  • Kopin IJ (1987) MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson’s disease. Environ Health Perspect 75:45–51

    PubMed Central  CAS  PubMed  Google Scholar 

  • Koprich JB, Reske-Nielsen C, Mithal P et al (2008) Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation 5:8

    PubMed Central  PubMed  Google Scholar 

  • Kortekaas R, Leenders KL, van Oostrom JC et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57(2):176–179

    CAS  PubMed  Google Scholar 

  • Krüger R, Kuhn W, Müller T et al (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Ann Neurol 18(2):106–108

    Google Scholar 

  • Kunikowska G, Jenner P (2001) 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res 922(1):51–64

    CAS  PubMed  Google Scholar 

  • Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M et al (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156(1):50–61

    CAS  PubMed  Google Scholar 

  • L’Episcopo F, Tirolo C, Caniglia S et al (2010) Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neuroinflammation. 7:83

    PubMed Central  PubMed  Google Scholar 

  • L’Episcopo F, Tirolo C, Testa N et al (2011) Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res 14(4):411–424

    PubMed  Google Scholar 

  • Langston JW, Forno LS, Tetrud J et al (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598–605

    CAS  PubMed  Google Scholar 

  • Larsen KE, Schmitz Y, Troyer MD et al (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26(46):11915–11922

    CAS  PubMed  Google Scholar 

  • Lee HJ, Chung KC (2012) PINK1 positively regulates IL-1β-mediated signaling through Tollip and IRAK1 modulation. J Neuroinflammation 9:271

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lee HJ, Jang SH, Kim H et al (2012a) PINK1 stimulates interleukin-1β-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. Cell Mol Life Sci 69(19):3301–3315

    CAS  PubMed  Google Scholar 

  • Lee BD, Shin JH, VanKampen J et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med 16(9):998–1000

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lee MK, Stirling W, Xu Y et al (2002) Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 –> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 99(13):8968–8973

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lee JK, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson’s disease. J Neuroimmune Pharmacol 4(4):419–429

    PubMed Central  PubMed  Google Scholar 

  • Lee KW, Zhao X, Im JY et al (2012b) Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 7(1):e29935

    PubMed Central  CAS  PubMed  Google Scholar 

  • Li Z, Arnaud L, Rockwell P et al (2004) A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells. J Neurochem 90(1):19–28

    CAS  PubMed  Google Scholar 

  • Li M, Dai FR, Du XP et al (2012) Neuroprotection by silencing Inos expression in a 6-OHDA model of Parkinson’s disease. J Mol Neurosci 48(1):225–233

    PubMed  Google Scholar 

  • Li X, Moore DJ, Xiong Y et al (2010a) Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem 285(38):29569–29576

    PubMed Central  CAS  PubMed  Google Scholar 

  • Li X, Patel JC, Wang J et al (2010b) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J Neurosci 30(5):1788–1797

    PubMed Central  CAS  PubMed  Google Scholar 

  • Lin X, Parisiadou L, Sgobio C et al (2012) Conditional expression of Parkinson’s disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 32(27):9248–9264

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ling ZD, Chang Q, Lipton JW et al (2004) Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 124(3):619–628

    CAS  PubMed  Google Scholar 

  • Liou HH, Chen RC, Tsai YF (1996) Effects of paraquat on the substantia nigra of the Wistar rats: neurochemical, histological, and behavioral studies. Toxicol Appl Pharmacol 137(1):34–41

    CAS  PubMed  Google Scholar 

  • Liu M, Bing G (2011) Lipopolysaccharide animal models for Parkinson’s disease. Parkinsons Dis 2011:327089

    PubMed Central  PubMed  Google Scholar 

  • Liu J, Guo YM, Hirokawa M et al (2012 ) A synthetic double-stranded RNA, poly I:C, induces a rapid apoptosis of human CD34(+) cells. Exp Hematol 40(4):330–341

    CAS  PubMed  Google Scholar 

  • Liu J, Wang MW, Gu P et al (2010) Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice. Brain Res 1345:213–220

    CAS  PubMed  Google Scholar 

  • Lücking CB, Dürr A, Bonifati V et al (2000) Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 342(21):1560–1567

    PubMed  Google Scholar 

  • Luk KC, Kehm V, Carroll J et al (2012a) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949–953

    PubMed Central  CAS  PubMed  Google Scholar 

  • Luk KC, Kehm VM, Zhang B et al (2012b) Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 209(5):975–986

    PubMed Central  CAS  PubMed  Google Scholar 

  • Machado A, Herrera AJ, Venero JL et al (2011) Inflammatory animal model for Parkinson’s disease: the intranigral injection of LPS induced the inflammatory process along with the selective degeneration of nigrostriatal dopaminergic neurons. ISRN Neurol 2011:476158

    PubMed Central  CAS  PubMed  Google Scholar 

  • Maekawa T, Mori S, Sasaki Y et al (2012) The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener 7:15

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mangano EN, Litteljohn D, So R et al (2012) Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways. Neurobiol Aging 33(7):1411–1426

    CAS  PubMed  Google Scholar 

  • Manning-Bog AB, McCormack AL, Li J et al (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277(3):1641–1644

    CAS  PubMed  Google Scholar 

  • Marinova-Mutafchieva L, Sadeghian M, Broom L et al (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. J Neurochem 110(3):966–975

    CAS  PubMed  Google Scholar 

  • Martin LJ, Pan Y, Price AC et al (2006) Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26(1):41–50

    CAS  PubMed  Google Scholar 

  • Masliah E, Rockenstein E, Veinbergs I et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265–1269

    CAS  PubMed  Google Scholar 

  • Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T et al (2013) Prion-like spreading of pathological α-synuclein in brain. Brain 136(Pt 4):1128–1138

    PubMed Central  PubMed  Google Scholar 

  • Matsui H, Gavinio R, Asano T et al (2013) PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates. Hum Mol Genet 22(12):2423–2434

    CAS  PubMed  Google Scholar 

  • Mazzio EA, Reams RR, Soliman KF (2004) The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res 1–2:24–29

    Google Scholar 

  • McClain JA, Phillips LL, Fillmore HL et al (2009) Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration. Neurosci Lett 460(1):27–31

    CAS  PubMed  Google Scholar 

  • McCoy MK, Martinez TN, Ruhn KA et al (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 26(37):9365–9375

    PubMed Central  CAS  PubMed  Google Scholar 

  • McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45

    PubMed Central  PubMed  Google Scholar 

  • McGeer PL, Itagaki S, Boyes BE et al (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38(8):1285–1291

    CAS  PubMed  Google Scholar 

  • McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12(Suppl 2):S1–S6

    CAS  PubMed  Google Scholar 

  • McGeer PL, Schwab C, Parent A et al (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54(5):599–604

    CAS  PubMed  Google Scholar 

  • Mena MA, García de Yébenes J (2008) Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia. Neuroscientist 14(6):544–560

    CAS  PubMed  Google Scholar 

  • Miake H, Mizusawa H, Iwatsubo T, Hasegawa M (2002) Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 277(21):19213–19219

    CAS  PubMed  Google Scholar 

  • Miklya I, Goltl P, Hafenscher F et al (2014) The role of parkin in Parkinson’s disease. Neuropsychopharmacol Hung 16(2):67–76

    PubMed  Google Scholar 

  • Miller RM, Kiser GL, Kaysser-Kranich T et al (2007) Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp Neurol 204(1):421–432

    CAS  PubMed  Google Scholar 

  • Mitra S, Chakrabarti N, Bhattacharyya A (2011) Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation 8:163

    PubMed Central  CAS  PubMed  Google Scholar 

  • Moehle MS, Webber PJ, Tse T et al (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32(5):1602–1611

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mogi M, Togari A, Tanaka K et al (2000) Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett 289(3):165–168

    CAS  PubMed  Google Scholar 

  • Mosharov EV, Staal RG, Bové J et al (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26(36):9304–9311

    CAS  PubMed  Google Scholar 

  • Mount MP, Lira A, Grimes D et al (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27(12):3328–3337

    CAS  PubMed  Google Scholar 

  • Mulcahy P, O’Doherty A, Paucard A, O’Brien T et al (2013) The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson’s disease-associated pesticide, rotenone, in rats. Behav Brain Res 15(243):6–15

    Google Scholar 

  • Na SJ, DiLella AG, Lis EV et al (2010) Molecular profiling of a 6-hydroxydopamine model of Parkinson’s disease. Neurochem Res 35(5):761–772

    CAS  PubMed  Google Scholar 

  • Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson’s disease. Neurosci Res 29(2):99–111

    CAS  PubMed  Google Scholar 

  • Nemani VM, Lu W, Berge V et al (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66–79

    PubMed Central  CAS  PubMed  Google Scholar 

  • Nguyen TA, Frank-Cannon T, Martinez TN et al (2013) Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation 10:50

    PubMed Central  CAS  PubMed  Google Scholar 

  • Oestreicher E, Sengstock GJ, Riederer P et al (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660(1):8–18

    CAS  PubMed  Google Scholar 

  • Ohnuki T, Nakamura A, Okuyama S et al (2010) Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson’s disease. Brain Res 1346:26–42

    CAS  PubMed  Google Scholar 

  • Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173(6):3916–3924

    CAS  PubMed  Google Scholar 

  • Orenstein SJ, Kuo SH, Tasset I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16(4):394–406

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pabon MM, Bachstetter AD, Hudson CE et al (2011) CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. J Neuroinflammation 8:9

    PubMed Central  CAS  PubMed  Google Scholar 

  • Paisán-Ruíz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595–600

    PubMed  Google Scholar 

  • Park B, Yang J, Yun N et al (2010) Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model. Neurochem Int 57(1):16–32

    CAS  PubMed  Google Scholar 

  • Paterna JC, Leng A, Weber E et al (2007) DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther 15:698–704

    CAS  PubMed  Google Scholar 

  • Perez FA, Curtis WR, Palmiter RD (2005) Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci 6:71

    PubMed Central  PubMed  Google Scholar 

  • Perumal AS, Gopal VB, Tordzro WK et al (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29(5):699–701

    CAS  PubMed  Google Scholar 

  • Pierre SR, Lemmens MA, Figueiredo-Pereira ME (2009) Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson’s disease in mice. J Neuroinflammation 6:18

    PubMed Central  PubMed  Google Scholar 

  • Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047

    CAS  PubMed  Google Scholar 

  • Poon HF, Frasier M, Shreve N et al (2005) Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice–a model of familial Parkinson’s disease. Neurobiol Dis 18(3):492–498

    CAS  PubMed  Google Scholar 

  • Potashkin JA, Blume SR, Runkle NK (2011) Limitations of animal models of Parkinson’s disease. Parkinsons Dis 2011:658083

    PubMed Central  Google Scholar 

  • Pott Godoy MC, Tarelli R, Ferrari CC et al (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease. Brain 131(Pt 7):1880–1894

    PubMed  Google Scholar 

  • Purisai MG, McCormack AL, Cumine S et al (2007) Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 25(2):392–400

    PubMed Central  CAS  PubMed  Google Scholar 

  • Pycock CJ (1980) Turning behaviour in animals. Neuroscience 5(3):461–514

    CAS  PubMed  Google Scholar 

  • Qin L, Liu Y, Wang T et al (2004) NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279(2):1415–1421

    Google Scholar 

  • Qin L, Wu X, Block ML et al (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55(5):453–462

    PubMed Central  PubMed  Google Scholar 

  • Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119–145

    CAS  PubMed  Google Scholar 

  • Ransom BR, Kunis DM, Irwin I et al (1987) Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 75(3):323–328

    CAS  PubMed  Google Scholar 

  • Reynolds AD, Stone DK, Hutter JA, Benner EJ et al (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184(5):2261–2271

    PubMed Central  CAS  PubMed  Google Scholar 

  • Rezai-Zadeh K, Gate D, Town T (2009) CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 4(4):462–475

    PubMed Central  PubMed  Google Scholar 

  • Riachi NJ, LaManna JC, Harik SI (1989) Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. J Pharmacol Exp Ther 249(3):744–748

    CAS  PubMed  Google Scholar 

  • Rochet JC, Outeiro TF, Conway KA et al (2004) Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson’s disease. J Mol Neurosci 23(1–2):23–34

    CAS  PubMed  Google Scholar 

  • Rockenstein E, Mallory M, Hashimoto M et al (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68(5):568–578

    CAS  PubMed  Google Scholar 

  • Rockenstein E, Nuber S, Overk CR, Ubhi K et al (2014) Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (in press)

    Google Scholar 

  • Ross OA, Braithwaite AT, Skipper LM et al (2008) Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 63(6):743–750

    CAS  PubMed  Google Scholar 

  • Roy A, Ghosh A, Jana A et al (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLoS One 7(6):e38113

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sadeghian M, Marinova-Mutafchieva L, Broom L et al (2012) Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol 246(1–2):69–77

    CAS  PubMed  Google Scholar 

  • Salama M, Arias-Carrión O (2011) Natural toxins implicated in the development of Parkinson’s disease. Ther Adv Neurol Disord 4(6):361–373

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sanchez-Guajardo V, Annibali A, Jensen PH et al (2013a) α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory t cell recruitment in a rat model. J Neuropathol Exp Neurol 72(7):624–645

    CAS  PubMed  Google Scholar 

  • Sanchez-Guajardo V, Barnum CJ, Tansey MG et al (2013b) Neuroimmunological processes in Parkinson’s disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5(2):113–139

    CAS  PubMed  Google Scholar 

  • Sanchez-Guajardo V, Febbraro F, Kirik D et al (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS One 5(1):e8784

    PubMed Central  PubMed  Google Scholar 

  • Sánchez-Pernaute R, Ferree A, Cooper O et al (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation 1(1):6

    PubMed Central  PubMed  Google Scholar 

  • Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318(1):215–224

    PubMed  Google Scholar 

  • Sekiyama K, Sugama S, Fujita M et al (2012) Neuroinflammation in Parkinson’s disease and related disorders: a lesson from genetically manipulated mouse models of α-synucleinopathies. Parkinsons Dis. doi:10.1155/2012/271732

    PubMed Central  PubMed  Google Scholar 

  • Selvakumar GP, Janakiraman U, Essa MM, Thenmozhi AJ et al (2014) Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson׳s disease. Brain Res S0006–8993(14):00358

    Google Scholar 

  • Shaikh SB, Nicholson LF (2009) Effects of chronic low dose rotenone treatment on human microglial cells. Mol Neurodegener 4:55

    PubMed Central  PubMed  Google Scholar 

  • Sherer TB, Betarbet R, Kim JH et al (2003a) Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 341(2):87–90

    CAS  PubMed  Google Scholar 

  • Sherer TB, Betarbet R, Testa CM et al (2003b) Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci 23(34):10756–10764

    CAS  PubMed  Google Scholar 

  • Sherer TB, Kim JH, Betarbet R et al (2003c) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179(1):9–16

    CAS  PubMed  Google Scholar 

  • Shimizu K, Ohtaki K, Matsubara K et al (2001) Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat. Brain Res 906(1–2):135–142

    CAS  PubMed  Google Scholar 

  • Shimoji M, Pagan F, Healton EB et al (2009) CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson’s disease. Neurotox Res 16(3):318–328

    CAS  PubMed  Google Scholar 

  • Shin JH, Ko HS, Kang H et al (2011) PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 144:689–702

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sindhu KM, Saravanan KS, Mohanakumar KP (2005) Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 1–2:25–34

    Google Scholar 

  • Singleton AB, Farrer M, Johnson J et al (2003) Alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841

    CAS  PubMed  Google Scholar 

  • Solano RM, Casarejos MJ, Menéndez-Cuervo J et al (2008) Glial dysfunction in parkin null mice: effects of aging. J Neurosci 28(3):598–611

    CAS  PubMed  Google Scholar 

  • Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840

    CAS  PubMed  Google Scholar 

  • Sriram K, Matheson JM, Benkovic SA et al (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J 16(11):1474–1476

    CAS  PubMed  Google Scholar 

  • Staal RG, Hananiya A, Sulzer D (2008) PKC theta activity maintains normal quantal size in chromaffin cells. J Neurochem 105(5):1635–1641

    CAS  PubMed  Google Scholar 

  • Su X, Maguire-Zeiss KA, Giuliano R et al (2008) Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging 29(11):1690–1701

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sulzer D, Surmeier DJ (2013) Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov Disord 28(1):41–50

    PubMed Central  CAS  PubMed  Google Scholar 

  • Swanson CR, Joers V, Bondarenko V et al (2011) The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8:91

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tanaka S, Ishii A, Ohtaki H et al (2013) Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation 10(1):143

    PubMed Central  PubMed  Google Scholar 

  • Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518

    PubMed Central  CAS  PubMed  Google Scholar 

  • Taylor JM, Main BS, Crack PJ (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. Neurochem Int 62(5):803–819

    CAS  PubMed  Google Scholar 

  • Theodore S, Cao S, McLean PJ et al (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67(12):1149–1158

    PubMed Central  CAS  PubMed  Google Scholar 

  • Thomas B, von Coelln R, Mandir AS et al (2007) MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis 26:312–322

    PubMed Central  CAS  PubMed  Google Scholar 

  • Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease. PLoS One 7(4):e34138

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tobón-Velasco JC, Limón-Pacheco JH, Orozco-Ibarra M, Macías-Silva M et al (2013) 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-κB factors. Toxicology 8(304):109–119

    Google Scholar 

  • Tofaris GK, Garcia Reitböck P, Humby T et al (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci v26(15):3942–50

    Google Scholar 

  • Tomás-Camardiel M, Venero JL, de Pablos RM et al (2004) In vivo expression of aquaporin-4 by reactive microglia. J Neurochem 91(4):891–899

    PubMed  Google Scholar 

  • Tran TA, Nguyen AD, Chang J et al (2011) Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One 6(8):e23660

    PubMed Central  CAS  PubMed  Google Scholar 

  • Tufekci KU, Genc S, Genc K (2011) The endotoxin-induced neuroinflammation model of Parkinson’s disease. Parkinsons Dis 2011:487450

    PubMed Central  PubMed  Google Scholar 

  • Tufekci KU, Meuwissen R, Genc S et al (2012) Inflammation in Parkinson’s disease. Adv Protein Chem Struct Biol. doi:10.1016/B978-0-12-398314-5.00004-0

    PubMed  Google Scholar 

  • Ulusoy A, Decressac M, Kirik D et al (2010) Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson’s disease. Prog Brain Res 184:89–111

    CAS  PubMed  Google Scholar 

  • Unger EL, Eve DJ, Perez XA et al (2006) Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis. 21(2):431–443

    CAS  PubMed  Google Scholar 

  • Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304:1158–1160

    CAS  PubMed  Google Scholar 

  • Vázquez-Claverie M, Garrido-Gil P, San Sebastián W et al (2009) Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J Neuropathol Exp Neurol 68(9):977–984

    PubMed  Google Scholar 

  • Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57–71

    PubMed Central  CAS  PubMed  Google Scholar 

  • von Coelln R, Kügler S, Bähr M, Weller M et al (2001) Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J Neurochem 77(1):263–273

    Google Scholar 

  • Von Coelln R, Thomas B, Savitt JM et al (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci 101:10744–10749

    Google Scholar 

  • Wachter B, Schürger S, Rolinger J et al (2010) Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. Cell Tissue Res. 342(2):147–160

    CAS  PubMed  Google Scholar 

  • Wang AL, Liou YM, Pawlak CR et al (2010) Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 208(1):38–46

    PubMed  Google Scholar 

  • Wang Q, Shin EJ, Nguyen XK et al (2012) Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 9:124

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wang XJ, Zhang S, Yan ZQ et al (2011) Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK. Free Radic Biol Med 50(9):1094–1106

    CAS  PubMed  Google Scholar 

  • Watson MB, Richter F, Lee SK et al (2012) Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 237(2):318–334

    PubMed Central  CAS  PubMed  Google Scholar 

  • Wilms H, Rosenstiel P, Romero-Ramos M et al (2009) Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int J Immunopathol Pharmacol 22(4):897–909

    CAS  PubMed  Google Scholar 

  • Wu SY, Wang TF, Yu L et al (2011) Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. Brain Behav Immun 25(1):135–146

    CAS  PubMed  Google Scholar 

  • Yadav S, Gupta SP, Srivastava G et al (2012) Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. Neurochem Res 37(4):875–884

    CAS  PubMed  Google Scholar 

  • Yasuda Y, Shimoda T, Uno K et al (2008) The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 204(1–2):43–51

    CAS  PubMed  Google Scholar 

  • Yu Z, Xu X, Xiang Z et al (2010) Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One 5(4):e9956

    PubMed Central  PubMed  Google Scholar 

  • Zarranz JJ, Alegre J, Gómez-Esteban JC et al (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164–173

    CAS  PubMed  Google Scholar 

  • Zhang ZJ, Cheang LC, Wang MW et al (2011a) Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol 32(1):27–40

    PubMed  Google Scholar 

  • Zhang S, Wang XJ, Tian LP et al (2011b) CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease. J Neuroinflammation 8:154

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zhang W, Phillips K, Wielgus et al (2011c) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson’s disease. Neurotox Res 19:63–72

    PubMed Central  PubMed  Google Scholar 

  • Zhang Z, Zhang K, Du X et al (2012) Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration. Mol Med Rep 5(2):562–566

    CAS  PubMed  Google Scholar 

  • Zhou H, Falkenburger BH, Schulz JB et al (2007a) Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 3:242–250

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zhou F, Wu JY, Sun XL et al (2007b) Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32(12):2570–2580

    CAS  PubMed  Google Scholar 

  • Zhou H, Huang C, Tong J et al (2011) Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci 7(6):753–761

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zhou F, Yao HH, Wu JY et al (2008) Opening of microglial K(ATP) channels inhibits rotenone-induced neuroinflammation. J Cell Mol Med 12(5A):1559–1570

    PubMed Central  CAS  PubMed  Google Scholar 

  • Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Columbia University Medical Center, New York, NY, 10032, USA

    Carolina Cebrián & David Sulzer

  2. Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York, NY, 10032, USA

    John D. Loike

  3. Departments of Psychiatry and Pharmacology, Columbia University Medical Center, New York, NY, 10032, USA

    David Sulzer

Authors
  1. Carolina Cebrián
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Loike
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Sulzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Sulzer .

Editor information

Editors and Affiliations

  1. Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tübingen, Germany

    Hoa Huu Phuc Nguyen

  2. Dept of Experimental Medical Science, Lund University, Lund, Sweden

    M. Angela Cenci

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Cebrián, C., Loike, J.D., Sulzer, D. (2014). Neuroinflammation in Parkinson’s Disease Animal Models: A Cell Stress Response or a Step in Neurodegeneration?. In: Nguyen, H., Cenci, M. (eds) Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Current Topics in Behavioral Neurosciences, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2014_356

Download citation

Publish with us

Policies and ethics

Search

Navigation